MISSION: EUROPA DONNA - The European Breast Cancer Coalition (ED) is an independent, non-profit pan-European coalition of affiliated grassroots groups whose mission is to ensure that all women have access to accurate information and the highest quality breast cancer screening, diagnosis and treatment. We are widely recognised to be Europe`s BC advocacy organisation, with 17 years experience advocating for evidence-based best practice breast services.

VISION: ED provides critically important advocacy, education and information with the aim of:
- greatly INCREASING EARLY DETECTION and thereby drastically DECREASING MORTALITY resulting from breast cancer
- bringing the QUALITY OF TREATMENT to the highest level for ALL women suffering from breast cancer and thereby DECREASING MORTALITY resulting from the disease
- increasing PREVENTION, by promoting and educating all European women about healthy lifestyle practices

ED`s general objectives are its Ten Goals, which are based on the aims enshrined in its Constitution. We seek: to promote the dissemination and exchange of factual, up-to-date information on breast cancer throughout Europe; to promote breast awareness; to emphasise the need for appropriate screening and early detection; to campaign for the provision of optimum treatment; to ensure provision of quality supportive care throughout and after treatment; to advocate appropriate training for health professionals; to acknowledge good practice and promote its development; to demand regular quality assessment of medical equipment; to ensure that all women understand fully any proposed treatment options, including entry into clinical trials and their right to a second opinion; to promote the advancement of breast cancer research.

VALUES: ED provides women in member countries with scientifically proven info, evidence-based education and tools, a sense of cross-border solidarity and the collective power necessary to bring about change while reducing inequalities betw countries.

The above are communicated to stakeholders on ED websites, publications and at events.


Orphanet is the world-reference portal dedicated to information on rare diseases (RD) and orphan drugs (OD) It was created in 1997 at the French National Institute of Health and Medical Research in Paris. It is coordinated by INSERM US 14 and the network involves now 38 countries.
The overriding aim of ORPHANET is to provide the community at large with a comprehensive set of information on RD and OD and attached services in Member States, to contribute to the improvement of the diagnosis, care and treatment of patients with RD.
Orphanet includes an inventory of 6000 RD, an encyclopaedia in 6 languages, a directory of health professionals (17000), expert clinics (5600), medical laboratories (1600), clinical trials (1700), research projects (4500), networks, registries (1300), patient organisations (2400), and information on OD and on drugs intended for rare diseases. All the MS have now an Orphanet national website published in their national language(s). The encyclopaedia of RD is available in English, French, German, Italian, Spanish, and Portuguese,Dutch, and for some diseases in Finnish, Greek and Polish. The portal is accessed daily by over 20,000 users from over 200 countries. Half of them are regular users. More than 10,500,000 documents are downloaded every year.
Orphanet has been developed through several rounds of funding, to include EU co-funding alongside other resources. In its current development phase, the network aims to develop tools for the partners as to empower them to collect data at national level and publish them, and in general tools to upgrade the quality of the database and ease its update and validation. In addition, the current 2014 work plan requires further work on the inventory and classification of RD, which has proven difficult due to delays in the overall review of the International Classification of Diseases.
Currently, Orphanet is co-funded through the ORPHANET Europe JA (alongside other funding sources –see section 1.5.5.). The activities which are included in the ORPHANET 2014 Operating Grant do not in any way overlap with those that are implemented through the Joint Action, which ends on 30/03/2014.





ENSP is an international non-profit association, created in 1997 under Belgium law, which aims to reduce tobacco consumption & to develop a common strategy amongst organisations active in tobacco control throughout Europe, by sharing information & experience, through co-ordinated activities & projects, by creating synergies among public health advocates thus increasing their capacity to direct their actions more effectively. ENSP acts as the lynchpin for its members creating a central cohesive force for the European tobacco control movement.

ENSP’s vision for the future is to eliminate the suffering of European citizens caused by ill health & early death due to tobacco-related diseases. We want children & young people to be able to grow up without being targets of tobacco industry marketing seeking to lure them into a lifetime of addiction. We want clean air unpolluted by tobacco smoke for all European citizens. ENSP’s strategic goal is to make our continent completely smoke-free by 2040 & our first objective is to work towards full implementation of the FCTC in Europe by 2020.

Given that tobacco control is at different stages in different European countries, ENSP applies the best & most effective evidence in policy & practice to work together towards a shared goal. ENSP members can take advantage of past experience in other countries & adapt such experience to their own needs. ENSP members work together to agree on a common policy & speak together in one voice, thus strengthening the European tobacco control effort & reinforcing European public health messages.

To eliminate the use of tobacco products in Europe, ENSP believes above all that all European countries need to implement comprehensive tobacco control strategies, including high taxes, comprehensive bans on direct & indirect advertising of tobacco, smoking bans in public & all workplaces, introduce strong & large (80%) textual & pictorial warnings on standardised tobacco packages.



Mission
EFA is aiming to be a powerful European network of allergy, asthma and COPD patients’ organisations that:
1. Advocates at the EU level for the needs of patients of these disease areas,
2. Values all members equally,
3. Implements best practices
4. Creates patient-driven projects
5. Cooperates with healthcare professionals, scientists and other stakeholders and NGOs in order to achieve its goals, implement values and have holistic approaches to solving health & care problems which directly affect patients with allergy, asthma and COPD.
Vision
EFA is dedicated to making Europe a place where people with allergies, asthma and COPD
- have the right to the best quality of care and safe environment,
- live uncompromised lives and
- are actively involved in all decisions influencing their health.
The organisation’s activities either integrate all elements of EFA’s vision or specifically focus upon one element individually so as to strengthen the overall position of allergy, asthma and COPD patients in Europe as EFA seeks long-term and meaningful solutions to the everyday issues of the patients it represents.
The core values of the EFA organisation are (1) patient perspective; (2) involvement; (3) sharing knowledge and experience; (4) partnership and cooperation; and (5) visibility and presence. The values are guiding principles for the organisation in all it`s activities. All of EFA’s activities and planning purposefully integrate these central values to demonstrate consistency in EFA’s work plans. As values shared by all its members, they foster trust between the national organisations and EFA, which designates the work performed in Brussels as overlapping with their own interests. These values also demonstrate EFA’s legitimacy to other organisations and actors working at the European level, which signals EFA’s mission and vision are exclusively driven by its membership and the patients whom they represent.
The mission and vision are visibly communicated at EFA website, and EFA publications.



The members of the European Network of Workplace Health Promotion (ENWHP) work together towards the vision `healthy employees in healthy organisations`. They are committed to the mission of developing and promoting good workplace health practice, which in turn contributes to a high level of health protection and sustainable economic and social development in Europe.
This vision is part of a broader vision at European policy level: The EU Lisbon Agenda identifies the goal for this decade to develop the EU region `to become the most competitive and dynamic knowledge-based economy in the world capable of sustainable economic growth with more and better jobs and greater social cohesion`. In this context workplace health promotion is part of the concept of quality in work with impacts on productivity, employment and social cohesion.

Healthy work impacts on the quality of working life and non-working life, and contributes to the level of health protection of communities and populations. It also impacts on microeconomic performance (productivity and innovation) and macroeconomic performance (efficiency of the health care, welfare and education sector, competitiveness of businesses at company, national and European level). Healthy work finally also contributes to social cohesion.

Healthy work is organised through processes both inside and outside enterprises that are based on the general management cycle, and specifically include infrastructure building and marketing.

With its vision and mission, ENWHP contributes especially to the reduction of health inequalities, to the development of a European health information system and to improving important health determinants with impacts on all relevant settings in working and non-working life.
